Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 308-311
DOI: 10.4103/ijmpo.ijmpo_159_20
Editorial Commentary

Blood and Bone Marrow Transplantation in India: Past, Present, and Future

Tapan K Saikia
Department of Medical Oncology, Prince Aly Khan Hospital, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Corrected by:

Erratum: Blood and Bone Marrow Transplantation in India: Past, Present, and FutureIndian J Med Paediatr Oncol 2020; 41(03): 627-627
DOI: 10.4103/0971-5851.293846

Prologue – The Global Scenario

Interest in the field of bone marrow transplantation was kindled in the early 1950s when laboratory and clinical experiments had begun in the US and France, triggered by the injury caused by nuclear warfare, during and post-WWII.[1] Animal and laboratory experiments provided proof of the principle.[2] As many patients with marrow aplasia and advanced leukemia had no curative treatment, clinical transplants were done as experimental procedures; however, due to lack of adequate knowledge in transplantation immunology and inadequate supportive care, most of them died either due to relapse, infection, or severe graft-versus-host disease (GVHD).[1],[3]

It took conviction of Thomas, first at Cooperstown, then at Fred Hutchison Cancer Research Center (FHCRC), Seattle, to pursue the procedure; better understanding of transplantation immunology through the works of many biologists, specially by Peter Medawar and dog experiments at Seattle, helped to find effective conditioning regimens and GVHD prophylaxis and soon led to a series of successful human allogeneic bone marrow transplants in acute leukemia and severe aplastic anemia.[4] By the late 1970s and early 1980s, the field exploded with many centers performing the procedure across the world.[5] In subsequent years, the indications expanded with autologous transplants for chemosensitive diseases such as lymphomas, myeloma, and some childhood tumors; dearth of matched sibling donors made it necessary to explore matched unrelated donors (MUDs) and umbilical cord blood as sources of hematopoietic stem cells.[6],[7] In recent years, the use of haploidentical transplants has shown exponential increment.



Publication History

Received: 15 April 2020

Accepted: 14 May 2020

Article published online:
28 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 de la Morena MT, Gatti RA. A history of bone marrow transplantation. Hematol Oncol Clin North Am 2011; 25: 1-5
    CrossrefPubMedGoogle Scholar
  • 2 Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956; 2: 626-7
    CrossrefPubMedGoogle Scholar
  • 3 Thomas ED, Lochte HLJr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-6
    CrossrefPubMedGoogle Scholar
  • 4 Thomas ED. A history of haemopoietic cell transplantation. Br J Haematol 1999; 105: 330-9
    CrossrefPubMedGoogle Scholar
  • 5 Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357: 1472-5
    CrossrefPubMedGoogle Scholar
  • 6 Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012; 119: 3908-16
    CrossrefPubMedGoogle Scholar
  • 7 Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, Rocha V. Milestones in umbilical cord blood transplantation. Br J Haematol 2011; 154: 441-7
    CrossrefPubMedGoogle Scholar
  • 8 Advani SH, Saikia TK. Bone marrow transplant in India. Bone Marrow Transplant ation 1994; 13: 731-2
    PubMedGoogle Scholar
  • 9 Chandy M. Innovative supportive care practices for stem cell transplantation in India. Biol Blood Marrow Transplant 2009; 15: 95-8
    CrossrefPubMedGoogle Scholar
  • 10 Mathews V, Srivastava A, Chandy M. Allogeneic stem cell transplantation in thalassemia major. Hematol Oncol N Am 2014; 28: 1187-2000
    Google Scholar
  • 11 George B, Mathews V, Melinkeri S, Lakshmi KM, Sharma A, Viswabandya A. et al. The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia-a retrospective analysis from three Indian centers. Clin Transplant 2013; 27: 923-9
    CrossrefPubMedGoogle Scholar
  • 12 Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A. et al Improved clinical outcomes of high risk B thalassemia major patients undergoing a HLA matched related alloegeneic stem cell transplant with s treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One 2013; 8: e61637
    CrossrefPubMedGoogle Scholar
  • 13 Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: A follow up report. Natl Med J India 2004; 17: 71-3
    PubMedGoogle Scholar
  • 14 Das M, Saikia TK, Advani SH, Parikh PM, Tawde S. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125-9
    CrossrefPubMedGoogle Scholar
  • 15 Punatar S, Mohite A, Gokarn A, Nayak L, Bonda A, Shanmugam K. et al. Leflunomide for chronic musculoskeletal graft versus host disease following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2020; 55: 467-9
    CrossrefPubMedGoogle Scholar
  • 16 Yadav SP. Bone marrow transplantation for primary immune deficiency disorders in India: Past, Present and Future. Indian Pediatr 2018; 55: 657-8
    CrossrefPubMedGoogle Scholar
  • 17 Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose posttransplant cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650
    CrossrefPubMedGoogle Scholar
  • 18 Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest 2019; 129: 2357-73
    CrossrefPubMedGoogle Scholar
  • 19 Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010; 47: 354-61
    CrossrefPubMedGoogle Scholar
  • 20 Gokbuget N, Dombert H, Bonifacio M, Reichle A, Graux C, Faul C. et al. Blinatumomab for MRD in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018; 131: 1522-31
    CrossrefPubMedGoogle Scholar
  • 21 Jacoby E. The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplant 2019; 54: 810-4
    CrossrefPubMedGoogle Scholar
  • 22 Bazarbachi AH, Al HamedR, Malard F, Mohty M, Bazarbachi A. Allogeneic transplant for FLT3 ITD mutated AML: A focus on FLT3 inhibitors before, during, and after transplant. Ther Adv Hematol 2019; 10: 2040620719882666
    CrossrefPubMedGoogle Scholar
  • 23 Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol 2018; 107: 138-50
    CrossrefPubMedGoogle Scholar
  • 24 Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-44
    CrossrefPubMedGoogle Scholar
  • 25 Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: Collateral damage. Bone Marrow Transplant 2020; 23: 1-2 DOI: 10.1038/s41409-020-0873-x. Online ahead of print
    CrossrefPubMedGoogle Scholar